Tokyo Tape
Sign in
← Suzuken

Quarterly report · Q2

9987.TEDINET S100PLBR
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.14T2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥2.24T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.10T2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥14.9bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥7.1bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥16.7bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥23.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥8.8bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥16.5bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥13.4bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥10.8bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥14.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥9.2bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥10.8bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥9.2bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.19Tat 2022-09-30Cons.Assets
Total assets¥1.14Tat 2022-03-31Cons.Assets
Total assets¥1.16Tat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥764.4bnat 2022-09-30Cons.Liabilities
Total liabilities¥723.7bnat 2022-03-31Cons.Liabilities
Net assets / equity¥429.1bnat 2022-09-30Cons.Net assets
Net assets / equity¥418.1bnat 2022-03-31Cons.Net assets
Net assets / equity¥422.4bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥132.9bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥141.4bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥155.8bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥168.2bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥159.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥168.8bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥28.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥9.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥15.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥37.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥1.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥17.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥11.6bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥7.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥123.362022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥92.862022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥163.192021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥103.752021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥108.922021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio35.9%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 40
SegmentItemPeriodValue
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥107.1bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥19.9bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥87.2bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥930m
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥43.2bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥43.2bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5m
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥644m
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.09T
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.07T
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥25.1bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.1bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥22.7bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.5bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥17.2bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.27T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.14T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥129.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥14.7bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥85.3bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥19.4bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥65.9bn
jpcrp040300-q2r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.2bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥44.0bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥44.0bn
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥13m
jpcrp040300-q2r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.0bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥1.06T
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.03T
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥25.8bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥3.5bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥21.9bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥6.0bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥15.9bn
jpcrp040300-q2r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥1.21T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥1.10T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥107.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥7.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 501
ItemContextValueUnit
Rent expenses on real estates noeCurrentYTDDuration157000000JPY
Other noePrior1YTDDuration66000000JPY
Other noeCurrentYTDDuration64000000JPY
Non operating expensesPrior1YTDDuration208000000JPY
Non operating expensesCurrentYTDDuration242000000JPY
Ordinary incomePrior1YTDDuration8806000000JPY
Ordinary incomeCurrentYTDDuration16717000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration11000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration2000000JPY
Gain on sales of investment securities eiPrior1YTDDuration4579000000JPY
Gain on sales of investment securities eiCurrentYTDDuration1000000JPY
Gain on transfer of business eiPrior1YTDDuration－JPY
Gain on transfer of business eiCurrentYTDDuration19000000JPY
Other eiPrior1YTDDuration23000000JPY
Other eiCurrentYTDDuration1000000JPY
Extraordinary incomePrior1YTDDuration4615000000JPY
Extraordinary incomeCurrentYTDDuration25000000JPY
Loss on sales and retirement of noncurrent assets elPrior1YTDDuration41000000JPY
Loss on sales and retirement of noncurrent assets elCurrentYTDDuration64000000JPY
Loss on reduction of noncurrent assets elPrior1YTDDuration20000000JPY
Loss on reduction of noncurrent assets elCurrentYTDDuration－JPY
Loss on sales of investment securities elPrior1YTDDuration0JPY
Loss on sales of investment securities elCurrentYTDDuration46000000JPY
Loss on valuation of investment securities elPrior1YTDDuration－JPY
Loss on valuation of investment securities elCurrentYTDDuration68000000JPY
Other elPrior1YTDDuration5000000JPY
Other elCurrentYTDDuration37000000JPY
Extraordinary lossPrior1YTDDuration67000000JPY
Extraordinary lossCurrentYTDDuration216000000JPY
Income before income taxesPrior1YTDDuration13354000000JPY
Income before income taxesCurrentYTDDuration16526000000JPY
Income taxesPrior1YTDDuration4129000000JPY
Income taxesCurrentYTDDuration5692000000JPY
Profit lossPrior1YTDDuration9225000000JPY
Profit lossCurrentYTDDuration10833000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration47000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration-16000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration9178000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration10850000000JPY
Profit lossPrior1YTDDuration9225000000JPY
Profit lossCurrentYTDDuration10833000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration2480000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration2356000000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration20000000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration53000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-128000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-196000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration331000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration1034000000JPY
Other comprehensive incomePrior1YTDDuration2704000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass